Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Minar

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Inflammatory Bowel Diseases|November 24, 2025
CAPTURE IBD: Advancing Precision Medicine in Pediatric IBDShova Subedi, Lindsey G Albenbergl, Julie A Bass, et al.
Gastroenterology|January 31, 2017
Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric PatientsMichael J Rosen, Rebekah Karns, Jefferson E Vallance, et al.
The American Journal of Gastroenterology|March 6, 2024
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's DiseaseDawn R Ebach, Traci W Jester, Joseph A Galanko, et al.
The American Journal of Gastroenterology|June 30, 2026
The Safety and Effectiveness of Early Anti-Tumor-Necrosis-Factor Therapy for Penetrating Crohn's Disease Complications in ChildrenBrad D Constant, Yixuan Feng, Jing Huang, et al.
The American Journal of Gastroenterology|October 18, 2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology|May 2, 2025
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
EGEMS (Washington, DC)|October 25, 2019
Implementing a Novel Quality Improvement-Based Approach to Data Quality Monitoring and Enhancement in a Multipurpose Clinical RegistryJesse Pratt, Daniel Jeffers, Eileen C King, et al.
Journal of Crohn'S & Colitis|August 10, 2020
Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's DiseaseYael Haberman, Phillip Minar, Rebekah Karns, et al.
Inflammatory Bowel Diseases|October 17, 2024
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's DiseaseJonathan Moses, Jeremy Adler, Shehzad A Saeed, et al.
Gastroenterology|April 2, 2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized TrialMichael D Kappelman, David A Wohl, Hans H Herfarth, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Inflammatory Bowel Diseases|November 24, 2025
CAPTURE IBD: Advancing Precision Medicine in Pediatric IBDShova Subedi, Lindsey G Albenbergl, Julie A Bass, et al.
Gastroenterology|January 31, 2017
Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric PatientsMichael J Rosen, Rebekah Karns, Jefferson E Vallance, et al.
The American Journal of Gastroenterology|March 6, 2024
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's DiseaseDawn R Ebach, Traci W Jester, Joseph A Galanko, et al.
The American Journal of Gastroenterology|June 30, 2026
The Safety and Effectiveness of Early Anti-Tumor-Necrosis-Factor Therapy for Penetrating Crohn's Disease Complications in ChildrenBrad D Constant, Yixuan Feng, Jing Huang, et al.
The American Journal of Gastroenterology|October 18, 2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology|May 2, 2025
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
EGEMS (Washington, DC)|October 25, 2019
Implementing a Novel Quality Improvement-Based Approach to Data Quality Monitoring and Enhancement in a Multipurpose Clinical RegistryJesse Pratt, Daniel Jeffers, Eileen C King, et al.
Journal of Crohn'S & Colitis|August 10, 2020
Mucosal Inflammatory and Wound Healing Gene Programs Reveal Targets for Stricturing Behavior in Pediatric Crohn's DiseaseYael Haberman, Phillip Minar, Rebekah Karns, et al.
Inflammatory Bowel Diseases|October 17, 2024
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's DiseaseJonathan Moses, Jeremy Adler, Shehzad A Saeed, et al.
Gastroenterology|April 2, 2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized TrialMichael D Kappelman, David A Wohl, Hans H Herfarth, et al.
Pageof 5